Purpose The purpose of this study was to compare inflammatory responses, tissue integration, and strength of the acellular dermal collagen matrices AlloDerm Ò
Introduction
Abdominal wall defects due to trauma or disease are a common problem in surgery. The repair of these defects can be difficult if there is significant loss of tissue that will not permit direct apposition of the abdominal wall structures. Traditionally, these repairs were accomplished with the use of synthetic meshes. While synthetic implants may be effective in providing a strong repair, closing abdominal wall defects with these materials may result in complications, such as foreign body reactions, infection, and adhesions to abdominal viscera. In addition, compared to native tissue, the compliance of synthetic meshes is reduced and may cause undesired sensation at the surgical site.
Several acellular collagen products have been developed and are being used clinically for tissue replacement/ reconstruction and the repair of abdominal wall defects [1] . Existing products include human-derived products (AlloDerm, Allomax, and FlexHD), as well as animal-derived dermal matrices that may be chemically crosslinked (Permacol TM Surgical Implant, CollaMend TM Implant from porcine source) or non-crosslinked (Veritas, Surgisis, SurgiMend, bovine; Strattice, XenMatrix, porcine).
AlloDerm Ò Regenerative Tissue Matrix (LifeCell Corp., Branchburg, NJ) represents one of the first decellularized biologic products to be marketed. It is a dermal matrix derived from human cadaveric skin, which undergoes a proprietary treatment to remove all cells, but is not crosslinked. The resulting acellular dermal matrix is freezedried and must be rehydrated prior to use. Due to the processing approach to remove the epidermal layer, AlloDerm is ''sided'', i.e., it is claimed to have an intact basement membrane side and a dermal side (LifeCell website). AlloDerm is widely used for a number of clinical applications, including breast reconstruction and ventral hernia repair [2] [3] [4] [5] . However, several recent reports have raised questions concerning the stretching of AlloDerm following abdominal wall reconstruction [6, 7] and its durability following reports of hernia recurrence rates of between 40 and 100% at 1 year [2, [8] [9] [10] .
Permacol TM Surgical Implant (Permacol) (Covidien, Mansfield, MA) is a porcine-derived crosslinked dermal matrix in which supplementary crosslinks are introduced into the collagen structure. Crosslinking increases the resistance of collagen to enzymatic breakdown [11] , but still permits cellular and vascular ingrowth [12] [13] [14] . Clinical data on Permacol's effectiveness in closing abdominal wall defects have been encouraging. Shaikh et al. [15] found that, with 18 months of follow-up, the recurrence rates (15%, 3 of 20 patients) for patients with Permacol repairs of their acute or chronic abdominal wall defects were about the same as the recurrence rates for patients who were closed with synthetic mesh. Cobb and Shaffer [16] found no difference in the recurrence rates between laparoscopically repaired hernias that were fixed with polypropylene mesh versus Permacol. Adedeji et al. [17] and Liyanage et al. [18] both reported case studies on individual patients in which large ventral hernias were repaired with Permacol implants. At 12 months, no recurrence of hernias or other complications were noted.
CollaMend TM Implant (from Bard Davol), like Permacol, is a porcine-derived acellular dermal matrix. It is also crosslinked via a proprietary process. Bard Davol recommends using CollaMend for hernias and other soft tissue repairs. It is supplied as a lyophilized product requiring brief rehydration before use. At this time, there is little scientific literature regarding CollaMend's biological properties. However, Chavarriaga et al. [19] recently reported on a series of 18 patients receiving CollaMend for the repair of complex abdominal wall defects. At 7.3 months follow-up, they report a 44.4% recurrence rate and that the prosthesis exhibited encapsulation rather than incorporation in all four patients where the mesh became infected and required removal.
Despite the fact that numerous biologic implant products are available for hernia repair and abdominal wall reconstruction, few comparative studies of implant performance have been reported. Recently, Butler et al. [20] compared two porcine acellular dermal matrices, non-crosslinked Strattice and crosslinked CollaMend, in a ventral hernia model over a 4-week period. They observed fewer adhesions and greater cellular infiltration with Strattice versus CollaMend. However, it is difficult to draw broad conclusions when comparing only two matrices over such a short period. The current study is designed to compare three dermal matrix products, AlloDerm, Permacol, and CollaMend, in an animal model for abdominal wall repair. Each of the manufacturers claim that their product integrates into the host tissue and becomes remodeled with time. Using a rat incisional hernia (ventral abdomen) model, we compared these three acellular dermal matrices for cellular and vascular ingrowth, the deposition of new collagen and changes in strength over a 6-month period, and attempt to discriminate between the two crosslinked porcine products.
Materials and methods
AlloDerm was purchased from LifeCell Corp., Branchburg, NJ. Tissue Science Laboratories, Inc. (Andover, MA, since purchased by Covidien) provided the Permacol implant. CollaMend was purchased from C.R. Bard, Murray Hill, NJ. All three implants were supplied at a 1-mm thickness. Collagen I, collagen III, and fibronectin antibodies were purchased from Chemicon (Temecula, CA). Elastase and matrix metalloprotease 9 (MMP-9) antibodies were purchased from Santa Cruz (Santa Cruz, CA). Hematoxylin and eosin (H&E) staining was performed by the core histology laboratory at the University of Massachusetts Medical School. Masson's trichrome and Verhoeff's stain kits were purchased from Sigma Chemical Co., St. Louis, MO. VectaStain ABC kits (horseradish peroxidase) were from Vector Laboratories, Inc. (Burlingame, CA).
Female Sprague-Dawley rats (250 g) were purchased from Taconic Labs (Hudson, NY). Under an approved Institutional Animal Care and Use Committee (IACUC) protocol, ventral abdominal wall defects were created as follows. Six rats per implant and time point were used. Rats were anesthetized with an intraperitoneal injection of ketamine (40-80 mg/kg) and xylazine (5-10 mg/kg) and given buprenorphine (0.02-0.08 mg/kg) IP as an analgesic. Ventral abdominal walls were shaved and scrubbed with Betadine and isopropyl alcohol (70%). A 3-cm midline incision starting just caudal to the xiphoid process was created and the skin detached from the underlying rectus muscles. A 1-cm 9 3-cm midline portion of the rectus sheath, along with a small amount of the rectus muscles from each side, was removed, along with the underlying peritoneum. The defect was repaired by the insertion of one of the three dermal collagen matrices. Under sterile conditions, each of the dermal matrices was cut into 1-cm 9 3-cm pieces and soaked in sterile saline for at least 30 min prior to implantation. The implant was sutured in place with a 1-2-mm overlap of the muscle using running polypropylene sutures (1-0 Prolene). The skin was closed with multiple interrupted sutures using 4-0 Vicryl. Finally, one or two wound clips were placed at the caudal portion of the incision and E-collars were placed on the rats for the initial 6-7 days after surgery. Following surgery, the rats received buprenorphine (0.02-0.08 mg/kg) at 12-h intervals for 48 h. Rats were euthanized and implants harvested at post-operative days 3, 7, 14, 30, 90, and 180. During harvest, the rats were examined for signs of seroma, infection, and tissue attachments or adhesion to abdominal viscera as secondary observations.
The control operated rats (two per group) received a 3-cm midline incision with the skin detached from the underlying rectus muscles as above. A 3-cm incision through the linea alba was made, followed by closure with 1-0 Prolene. The skin was closed with 4-0 Vicryl sutures as above. At the times indicated above, the rats were euthanized and the tissue surrounding the incision site harvested for histological analysis.
Harvested implants were either fixed in 4% paraformaldehyde at 4°C for subsequent histology or frozen at -20°C for later analysis. Fixed tissue samples were embedded in paraffin and 10-micron sections cut. Sections were stained with H&E, Masson's trichrome, or Verhoeff's stain. Additional sections were stained immunohistochemically for rat collagen I, rat collagen III, rat Fibronectin, rat elastase, and rat MMP-9.
For mechanical strength testing, the explanted matrices were carefully trimmed of extra host tissue, wrapped in saline-soaked gauze, and frozen at -80°C until all samples had been harvested. The day prior to testing, the samples were permitted to thaw refrigerated overnight. Duplicate samples of each matrix and at 1-month, 3-month, and 6-month time points were subjected to tensile strength testing using an Instron E1000 apparatus in the vertical position. The central portion of each explanted matrix sample was cut into a ''dog bone'' shape using a punch to ensure uniformity in the size of the samples being tested.
Results

Gross morphology
Rats were monitored daily for 10 days. Three of the rats receiving CollaMend implants were able to remove sutures and open the wounds, exposing the implant, which dehydrated. These animals were terminated early (18 h, 7, and 10 days). Two rats in the AlloDerm group and six rats in the Permacol group also removed sutures at the distal end of the incisions. In no case were the implants exposed. Wound clips were placed to reclose the incisions without further incident.
A single rat with a CollaMend implant developed an infection at the incision and was euthanized. Many rats developed visible seromas that were drained via needle aspiration (Table 1) . At 14 days post-implantation, rats receiving AlloDerm (40%) or Permacol (33%) exhibited lower seroma formation compared to CollaMend (83%). In each case, following drainage, the seromas resolved and, by 30 days, no visible seromas were noted for any of the rats, regardless of the implant type. Also, in harvesting the implants, little evidence of prior seromas could be detected. Of note, none of the control operated (sham) rats exhibited visible seromas.
Upon harvesting the implants, the degree and nature of adhesions to abdominal viscera were noted. Table 1 approximates the percentage of internal surface area covered by adhesions. In nearly all cases in which adhesions were observed, a single adhesion arose (with the exception of two animals) from the greater omentum. At day 14, one rat each receiving AlloDerm or CollaMend displayed a single adhesion to bowel. The adhesions were easily broken down with blunt dissection. The degree of adhesion to the omentum was greatest during the initial 14 days of implantation, with the extent to which the peritoneal surface was covered by adhesions declining at 30 days and beyond. Figure 1 depicts representative examples of each implant at various time points. For the AlloDerm implants at 6 months, the central portions of the implants were thin and translucent, with significant overgrowth from the periphery. The gross appearance of the Permacol and CollaMend implants at 6 months appeared similar to those harvested at 30 days. There was some vascularized overgrowth from the periphery, with a thin layer of tissue covering the peritoneal surface, but, in both cases, it was less than that noted with AlloDerm. For a few rats receiving CollaMend, the central portion of the implants appeared devoid of any tissue covering at 6 months, as shown in Fig. 1 .
Histology
The explanted dermal matrices were sectioned and stained with H&E, Masson's trichrome, or Verhoeff's stains. Fig. 2 . The AlloDerm implants exhibited rapid infiltration of inflammatory cells, with full penetration within 7 days. Cellular infiltration peaked much earlier in the AlloDerm implants, with blood vessel formation in the implant identifiable by 14 days, with thick channels of cellular infiltrate pushing apart the implant matrix. By 30 days, the AlloDerm implants were heavily infiltrated with inflammatory cells, the matrix was less well demarcated, and a few blood vessels were visible. By 90 days, the inflammatory cells were replaced with fibroblast-like cells and some adipocytes.
In contrast, at 14 days, the Permacol implants exhibited inflammatory cell penetration to about 20% of the implant thickness. At 30 days, ''cords'' of inflammatory cells were approaching the central portion of the implant, with a few blood vessels on the surface. A sparse, random distribution of fibroblast-like cells was noted throughout the Permacol implants at 90 days. The surface of the Permacol displayed a layer of newly deposited (based on the less intense staining) connective tissue that appeared adherent to and partially penetrating the Permacol.
A very different pattern was observed with the CollaMend implants. At the earliest times (up to 14 days), inflammatory cells were attached to the surfaces as thick coats frequently 20 or more cells in thickness, but with little penetration into the matrix. These surface coats appeared loosely attached and, in some cases, they could be seen detached from the implant, forming a capsule-like structure. By 30 days and later, this capsule-like structure became better defined. At the 180-day time point, cellular infiltration of the matrix only reached about 25% from each surface. Rarely did cells penetrate the full thickness of the CollaMend implants. In addition, the CollaMend implants at 6 months appeared to be encapsulated by a thin layer of connective tissue not adherent to the implant surface. Between the combination of the abundant inflammatory cells and the adhesions, it was difficult to discern the extent to which a mesothelial cell layer formed on the peritoneal surfaces of any of the implants. These results are summarized in Table 2 , with representative micrographs presented in Fig. 2 .
Sections of implants were stained with Masson's trichrome stain to enhance visualization of the extracellular matrix (blue). At the earliest time (day 3), the AlloDerm implants exhibited abundant cellular infiltration between collagen bundles. This progressed steadily, with less intense matrix staining noted at 30 days. In addition, the matrix appeared to be disorganized and fragmented. By 90 days, the cellular content of the matrix had decreased and the matrix appeared more organized, with many collagen bundles aligned.
Distinctly different patterns were seen with Permacol and CollaMend implants. Matrix staining was generally intense at all of the times examined. Permacol implants exhibited modest cellular and blood vessel infiltration, being noted as early as 1 month. At 6 months, while the majority of the matrix remained intact, some areas showed surface matrix alignment with a slightly less intense staining than the underlying matrix. We presume that this represents newly deposited matrix, with alignment similar to that observed with the AlloDerm implants. As with the H&E staining, little cell penetration was observed for the CollaMend implants even at the edges, where the implant was sutured to the rectus muscles. Verhoeff's stain is used to delineate elastin fibers and blood vessels by producing a brown/black reaction. Sections of the three implant materials were stained with Verhoeff's stain at the various times as above (Fig. 2) . At 7 days, the AlloDerm implants exhibited abundant staining of fibrous structures. By day 14, when the AlloDerm implants were heavily infiltrated with cells, the fibrous staining was replaced by abundant cellular staining that persisted at 30 days, while the matrix was still heavily cellularized. At 3 months, Verhoeff's staining of the AlloDerm implants was significantly reduced, though some faintly stained fibers and blood vessels were noted. At 6 months, the AlloDerm implant showed strong Verhoeff's staining throughout. Permacol implants exhibited surface staining at day 7, with some faint staining penetrating the implant by day 14. This was observed along what appeared to be pre-existing spaces between collagen bundles. By 6 months, clearly defined blood vessels could be observed and stained for elastin. The control, sham operated samples exhibited strong elastin staining within the connective tissue at all of the times examined. In contrast, staining in the CollaMend implants was confined to the surfaces throughout the 6-month study period.
Immunohistochemistry
Sections (paraformaldehyde-fixed and paraffin-embedded) of each implant at the given times of harvest were stained with a panel of antibodies recognizing rat extracellular matrix proteins and proteases. The antibodies were ratspecific to allow an evaluation of the extent to which newly deposited proteins accumulated within each of the three implanted matrices. Sections were stained for collagen types I and III, fibronectin, elastase, and MMP-9, and the results are summarized in Table 3 . At day 7, staining for all of the proteins was detected on the periphery of each implant. For the Permacol and CollaMend implants, the staining was noticeably less intense than that observed for the AlloDerm implants. Collagen III and elastase staining penetrated the AlloDerm implants 25-30% at day 7, while remaining essentially as surface staining for the Permacol and CollaMend implants. Collagen I and MMP-9 staining increased with time and showed penetration into the implant by 1 month in the AlloDerm samples. For the Permacol implants, collagen III and elastase exhibited strong staining by 1 month, with penetration nearing the center of the implants. Collagen I and MMP-9 staining lagged but eventually showed staining at the 6-month time point. For the CollaMend implants, only collagen III displayed intense staining eventually to the full thickness of the implant, but most intensely on the surfaces of connective tissue bundles. At 6 months, collagen I staining was readily visible, but staining for elastase and MMP-9 never developed as intensely as that observed for AlloDerm or Permacol. This observation of type III collagen staining preceding that of type I collagen is consistent with the observations that, during wound healing, type III collagen deposition occurs before type I collagen deposition. Particularly noticeable with the collagen III staining of the AlloDerm and Permacol implants, the orientation of the peripheral or surface collagen bundles at late times appeared to be more uniformly oriented when compared to the 3-or 7-day samples. Whether this apparent alignment is due to forces or stress placed on the implants will require additional analysis. With each of the implants, fibronectin staining was detected at all time points, suggesting that this antibody lacked specificity to distinguish between rat, human, and porcine fibronectin.
Mechanical testing
To determine the material properties of AlloDerm, Permacol, and CollaMend before and after 1, 3, and 6 months of implantation in a rat hernia model, uniaxial cyclic and failure tensile tests were performed. Modulus (intrinsic stiffness), stress and strain at failure, and maximum load were calculated for all groups. The ultimate tensile stress (UTS) and maximum load decrease with time of implantation. In general, for strength at all time points, CollaMend [ Permacol [ AlloDerm, with a maximum UTS of *12 MPa at 1 month for CollaMend and a minimum of *1 MPa at 6 months for AlloDerm (Fig. 3b) . No obvious trends in extensibility were observed; the strain at maximum load ranges from 10 to 30%. The moduli were highly variable, with no strong trends (Fig. 3c ) during test to failure; however, the Permacol samples appear to be the stiffest overall (15 MPa in 5% strain region and up to 75 MPa in failure tests). Due to the low number of samples in each group, the variability is quite large for all metrics. Statistical comparisons were not completed due to the low power. Overall, the AlloDerm samples are the weakest, least extensible, and least stiff of the three materials. The CollaMend explants were the strongest and most extensible, yet, the Permacol explants were the stiffest.
Discussion
A wide variety of acellular biological matrices have made their way into clinical use in recent years. They range from small intestine submucosa (Surgisis), urinary bladder matrix (UBM), and pericardial membranes (Veritas Collagen Matrix), to a number of acellular dermal matrices (human-derived AlloDerm and Flex HD, porcine Permacol and CollaMend, bovine SurgiMend). Some of these are chemically crosslinked and others are not. In each case, the manufacturers have provided data showing that cellular ingrowth and remodeling occurs over time. Liang et al. [21] reported on the effects of crosslinking in the cellular infiltration and tissue regeneration of bovine pericardium implants subcutaneously into rats. Pericardium samples were either fresh or crosslinked with genipin to 30, 60, or 95%. They report that both the fresh and 30% crosslinked samples were rapidly infiltrated and showed significant degradation. In contrast, cells were able to penetrate the 60 and 95% crosslinked samples. Cellular penetration of the 60% crosslinked samples were near 100% at 3 months, but never rose above 40% for the 95% crosslinked samples, even at 1 year. However, little information exists regarding direct comparisons of these dermal matrices within the same model. Here, using a rat incisional (ventral) hernia model, we compared AlloDerm, Permacol, and CollaMend with regard to cellular and vascular ingrowth, as well as new extracellular matrix protein deposition and changes in strength over a 6-month period. Each of the acellular dermal matrices, as well as the control operated animals, elicited an early inflammatory response. Seromas appeared in many animals, though the incidence of seroma formation in the CollaMend group was twice that for AlloDerm or Permacol. Upon draining via needle aspiration, the seromas resolved and were not noticeable at later times. None of the control operated animals exhibited seroma formation. At the earliest time examined (3 days), inflammatory cells (monocytic and polymorphonuclear leukocytes) were seen penetrating the AlloDerm matrix, while inflammatory cells were largely confined to a surface layer in the Permacol and CollaMend matrices. By 1 month, inflammatory cells had fully infiltrated the AlloDerm implants. Sparse cellular infiltration along ''tracts'' were seen penetrating to near the center of the Permacol implants, while in the CollaMend samples, inflammatory cells were confined to the surface, with only slight penetration. At 3 months, the inflammatory response had subsided and the AlloDerm matrix appeared to be well populated with fibroblasts and occasional blood vessels. Inflammatory cells were less abundant at 3 months in the Permacol and CollaMend implants as well. However, the presence of fibroblast-like cells was significantly less for both of these matrices. The Permacol implants did exhibit significantly deeper penetration of fibroblasts and blood vessels compared to CollaMend. By 6 months, a few adipose cells were seen within the AlloDerm implants near the junction with skeletal muscle, while modestly more fibroblast-like cellular ingrowth was seen for the other matrices. No adipose cells were noted in the Permacol or CollaMend explants.
The inflammatory response was confirmed by staining tissue sections with antibodies directed against rat elastase and MMP-9, two extracellular proteases secreted by neutrophils and macrophages. Table 3 summarizes these observations, with staining being the most pronounced at the implant surface initially, but penetrating well within the AlloDerm matrix by 14 and 30 days. This suggest a more rapid remodeling of AlloDerm compared with the notably slower penetration of the Permacol and CollaMend implants, with the latter showing the weakest cellular penetration. We also noted that, at 6 months, AlloDerm implants had become translucent, similar to what was reported by Gaertner et al. [7] . Taken together, the apparent rapid remodeling and observed translucent appearance of the AlloDerm at 6 months may relate to the 20% recurrence rate of hernias following AlloDerm repairs reported by Misra et al. [22] and to reports that AlloDerm does ''stretch'' over time [6, 7] .
To address matrix remodeling, tissue sections were immunostained for rat fibronectin, collagen I, and collagen III. Fibronectin staining was detected throughout each implant at all of the times examined, suggesting that this antibody lacked the ability to distinguish between rat, human, and porcine fibronectin. All three implants stained for collagen III, although staining was detected more rapidly in interior portions of the AlloDerm samples. Collagen I staining lagged behind that of collagen III and was never as robust in the Permacol or CollaMend samples compared to AlloDerm. From these observations, it appears that each matrix supports cellular and vascular ingrowth and matrix Fig. 3 Tensile strength testing. a An explanted CollaMend sample prior to and following cutting into the ''dog bone'' shape for mechanical testing. The two dots (India ink) allowed for video monitoring. b Results of the tensile stress testing of duplicate samples of each matrix at the indicated times of explant. Due to technical problems during testing, only single samples for Permacol at 1 month and AlloDerm at 6 months were included. c Modulus testing to failure remodeling to different extents, with AlloDerm exhibiting the fastest ingrowth, followed by Permacol, while CollaMend exhibited little cellular ingrowth and matrix deposition.
Upon harvesting implants at 3 and 6 months, the Permacol and CollaMend implants appeared largely intact. Histologically, these two matrix products did exhibit cellular infiltration suggestive of remodeling while retaining their durability. Blood vessels were easily visible on the fascial surfaces once the subcutaneous fascia was removed. In contrast, at 3 and 6 months, AlloDerm implants exhibited noticeable thinning, becoming translucent in some cases. Adhesions were largely via the greater omentum and not appreciably different between implants. Regardless of the implant type, adhesions were easily detached with a blunt probe. As noted in Table 1 , adhesions were typically a single adhesion arising from the greater omentum and covering significant portions of the peritoneal surface. With time, the extent of area covered by adhesion tissue declined for each implant type, except at the 180-day time point for AlloDerm, where adhesion coverage demonstrated an unanticipated increase.
Possibly the most critical issue in choosing an acellular biological matrix for soft tissue repair (hernias) relates to the long-term strength of the implant. Synthetic meshes such as Gore-Tex and polypropylene will remain and provide strength to the repair site until being removed surgically. Biological matrices, however, are intended to become incorporated into host tissue and eventually be replaced via the remodeling process. If this process is too rapid, the implant may not provide the requisite strength and stability as tissues heal. Misra et al. [22] reported on a retrospective analysis of 70 patients in which AlloDerm was used in abdominal wall hernia repair. Fourteen patients or 20% presented with recurrent hernias. Hsu et al. [23] evaluated the outcomes of 28 patients that underwent abdominal wall repair using Permacol. Three of the 28 (10.7%) patients developed a recurrent hernia. Little clinical information regarding CollaMend appears in the literature as yet. If the process is too slow or impeded, the implant could become encapsulated and excluded from the remodeling process. We did note a ''capsule-like'' structure forming around some of the CollaMend samples at 6 months, but not with all samples. This is consistent with what has been reported for CollaMend in the clinical setting (Chavarriaga et al. [19] ). Neither AlloDerm nor Permacol exhibited signs of encapsulation in any of the samples. Whether the observed encapsulation of CollaMend is related to the much higher rate of seroma formation or poor cell integration with this implant will require further analysis. Differences in processing and crosslinking agents may contribute to the difference between the two crosslinked matrices that we noted. With regard to the strength of the various implants tested here, CollaMend exhibited the overall greatest tensile strength at 6 months, followed by Permacol, while AlloDerm exhibited the lowest residual tensile strength at 6 months. This pattern is essentially the opposite as to what can be concluded regarding incorporation into host tissue and remodeling. AlloDerm exhibited the most rapid remodeling, followed by Permacol, with CollaMend being the slowest.
Our observations suggest that AlloDerm appears to remodel more rapidly than Permacol or CollaMend, but, at the same time, appears to lose strength more rapidly. This could account for the reported 20% hernia recurrence rate for this product observed by Misra et al. [22] . CollaMend, on the other hand, exhibited evidence of encapsulation and poor ingrowth, similar to that observed by Chavarriaga et al. [19] in their analysis of 18 patients undergoing abdominal wall reconstruction with this product. In addition, Butler et al. [20] recently reported on the comparison of Strattice (non-crosslinked) and CollaMend (crosslinked) porcine dermal collagen matrices in a guinea pig ventral hernia model. Our results comparing AlloDerm and CollaMend are quite similar to those of Butler et al. [20] . We also observe higher levels of adhesion and seroma formation (Table 1) with CollaMend. There appeared to be little cellular or vascular ingrowth of CollaMend at 6 months, while seeming to have become encapsulated. This is in contrast to the results with Permacol, also a crosslinked porcine dermal matrix. Permacol and AlloDerm compared favorably in regard to seroma and adhesion formation (Table 1) . Permacol did not appear to become encapsulated, but exhibited significant, albeit slower, cellular and vascular ingrowth compared to AlloDerm. Permacol retained greater strength than AlloDerm at 6 months, however. Others have reported the weakening and stretching of AlloDerm with time [6] [7] [8] [9] [10] . Previously, we reported that an explanted piece of Permacol 2 years postsurgery was fully infiltrated with fibroblasts and blood vessels, with no signs of encapsulation (O'Brien et al. [24] ).
Conclusion
Each of these acellular dermal matrices likely has a clinical application in which it may perform better that the others. No single matrix is likely to be useful for all applications. Key for the clinician and ultimate outcome of a surgical repair with a biological matrix is to choose the matrix best suited to the application. 
